Modes of RTK dimerization and downstream protein recruitment. (a) Structural model of the activated EGF–EGFR complex. On the extracellular side of the plasma membrane (colored gray and shown approximately to scale), the 2:2 EGF:EGFR complex is two-fold symmetric (dyad axis is vertical). The two receptors in the complex are colored cyan and purple (alternating light and dark coloring for the subdomains), and the two EGF molecules are colored orange (ribbon diagram with semi-transparent surface). The four subdomains of the EGFR ectodomain are, sequentially, L1–CR1–L2–CR2. The transmembrane helices are shown as cylinders, and linker segments (juxtamembrane regions [extra- and intracellular] and C-terminal tail) are drawn schematically as thick lines. On the cytoplasmic side, the two tyrosine kinase domains (N- and C-lobes colored dark and light, respectively) form an asymmetric dimer, with the C-lobe of one kinase domain (purple) interacting with the N-lobe of the other kinase domain (cyan). This interaction activates the second kinase domain (cyan) [10••]. The yellow spheres represent phosphotyrosine recruitment sites in the C-terminal tail of the cytoplasmic domain. The structures are derived from PDB codes 1IVO [48] and 1NQL [49] (ectodomain dimer) and 1M14 [50] (kinase dimer). (b) Structural model of the α₂β₂ insulin receptor with Grb14 bound. The insulin receptor ectodomain is two-fold symmetric (dyad axis is vertical) and consists, sequentially, of subdomains L1–CR1–L2–Fn1–Fn2–Fn3, of which L1–CR1–L2–Fn1–Fn2(N) are on the α chain and Fn2(C)–Fn3 are on the β chain (the chains are not distinguished in the figure). The tyrosine kinase domains (β chain) are colored as in (a). The BPS–SH2 portion of Grb14 (ribbon diagram with semi-transparent surface) binds to the kinase domain (2:2 complex) and inhibits catalytic activity. The SH2 domain (orange) mediates Grb14 dimerization and the BPS region (black) binds as a pseudosubstrate inhibitor in the kinase active site. The structures are derived from PDB codes 2DTG [16••] (ectodomain) and 2AUG and 2AUH [21•] (Grb14-IRK complex). Insulin is not bound to the ectodomain in this structure, but its presumed binding site (one of two equivalent sites) between L1 (α-chain 1) and Fn1 (α-chain 2) is indicated by the arrow. In both (a) and (b), the distance between the transmembrane helices is somewhat arbitrary, owing to the (presumed) flexible linkers connecting CR2 (a) and Fn3 (b).

Binding of small-molecule inhibitors to RTKs. The ATP-competitive inhibitors are shown in stick representation with a semi-transparent surface. Carbon atoms are colored yellow, oxygen atoms red, and nitrogen atoms blue. (a) Crystal structure of the tyrosine kinase domain of the EGFR kinase domain in complex with erlotinib (Tarceva) [50]. (b) Crystal structure of the tyrosine kinase domain of Kit in complex with imatinib (Gleevec) [51]. For both (a) and (b), the N-lobe of the kinase is colored dark gray, the C-lobe light gray, α-helix C (N-lobe) light blue, the catalytic loop (C-lobe) orange, and the activation loop (C-lobe) green. The activation loop in (a) is in an active state, whereas the activation loop in (b) is in an autoinhibited, inactive state. The ‘gatekeeper’ residue (Thr790 in EGFR, Thr670 in Kit), which when mutated causes drug resistance to both erlotinib and imatinib, is colored magenta (in the back of the N-lobe).